|
|
M Vincent, N J Samani, D Gauguier, J R Thompson, G M Lathrop, J Sassard
J Clin Invest. 1997;
100(8):2000
doi:10.1172/JCI119731
Abstract |
Full text
| PDF

I
n a backcross population (n = 281) derived from a cross of the Lyon hypertensive rat with Lyon normotensive rat, we investigated whether genetic factors influence the acute cardiovascular responses to pharmacological modulation of the renin-angiotensin system, the sympathetic nervous system, and the voltage-sensitive L-type calcium channels. Using microsatellite markers, a quantitative trait locus was identified and mapped on rat chromosome 2 that specifically influences the systolic (peak LOD score 4.4) and diastolic (peak LOD score 4.1) blood pressure responses to administration of a dihydropyridine calcium antagonist, PY108-068. The locus accounted for 10.3 and 10.4% of the total variances in the systolic and diastolic responses to PY108-068, respectively. In marked contrast, the locus had no effect on either basal blood pressure or on the responses to acute administration of a ganglionic blocking agent, trimetaphan, or of an angiotensin II subtype 1 receptor antagonist, losartan. These findings provide strong direct support for the paradigm that genetic factors may influence the response to antihypertensive drugs and suggest that the heterogeneity seen in the responses to different antihypertensive agents in human essential hypertension may have a significant genetic determination.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(12)
| Title and authors |
Publication |
Year |
Y27632, a Rho-activated kinase inhibitor, normalizes dysregulation in alpha1-adrenergic receptor-induced contraction of Lyon hypertensive rat artery smooth muscle.
Maria Regina Freitas, Masumi Eto, Jason A Kirkbride, Christa Schott, Jean Sassard, Jean-Claude Stoclet
|
Fundamental & Clinical Pharmacology
|
2009 |
Pharmacogenomics in Cardiovascular Medicine
John F. Carlquist, Jeffrey L. Anderson
|
Drug Dev. Res.
|
2004 |
Optimal blood pressure control and antihypertensive regimens in hypertensive renal disease: the potential of exploring the mechanisms of response variability
Menno J.A. Kocks, Dick de Zeeuw, Gerjan J. Navis
|
Current Opinion in Nephrology and Hypertension
|
2002 |
Antihypertensive pharmacogenetics: getting the right drug into the right patient
Stephen T. Turner, Gary L. Schwartz, Arlene B. Chapman, W. Dallas Hall, Eric Boerwinkle
|
Journal of Hypertension
|
2001 |
Use of gene markers to guide antihypertensive therapy
Stephen T. Turner, Gary L. Schwartz, Arlene B. Chapman, Eric Boerwinkle
|
Current Science Inc
|
2001 |
The Genomics of Cardiovascular Disorders
Patrizia Ferrari, Giuseppe Bianchi
|
Drugs
|
2000 |
Gene-environment interactions in hypertension
Zdenka Pausova, Johanne Tremblay, Pavel Hamet
|
Current Science Inc
|
1999 |
Use of animal models to search for candidate genes associated with essential hypertension
Margit Knoblauch, Klaus Lindpaintner
|
Current Science Inc
|
1999 |
Genes and Hypertension: Where we are and where we Should Go
Pavel Hamet
|
Clin Exp Hypertens
|
1999 |
In search of hypertension genes in Dahl salt-sensitive rats
Alan Y. Deng
|
Journal of Hypertension
|
1998 |
|